Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies

Current Medicinal Chemistry

Volumn 21, Issue 36, 2014, Pages 4186-4198

  Edagwa, Benson J ^a   Zhou, Tian ^b   McMillan, Joellyn M ^a   Liu, Xin Ming ^a,b   Gendelman, Howard E ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Dendrimers; Drug delivery systems; Gut associated lymphoid tissue; HIV; HIV reservoir targeted ART; Liposomes; Lymphoid tissues; Micelles; Nanomedicine; Polymeric nanoparticles

Indexed keywords

ANTIRETROVIRUS AGENT; DENDRIMER; LIPOSOME; NANOCONJUGATE; NANOPARTICLE; POLYMER; SOLID LIPID NANOPARTICLE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG CARRIER; MICELLE;

ANTIVIRAL THERAPY; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE INFECTION; LUNG INFECTION; LYMPHOCYTE; LYMPHOID TISSUE; MICELLE; NANOMEDICINE; NANOTECHNOLOGY; NEUTROPHIL; NONHUMAN; SUSPENSION; VIRUS CARRIER; BIOLOGICAL THERAPY; CHEMISTRY; HIV INFECTIONS;

ANTI-HIV AGENTS; CELL- AND TISSUE-BASED THERAPY; DENDRIMERS; DRUG CARRIERS; HIV INFECTIONS; HUMANS; LIPOSOMES; MICELLES; NANOMEDICINE; NANOPARTICLES;

EID: 84928674001     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140826114135     Document Type: Article

References (148)

1. Gomes, M. J.; Neves, J. D.; Sarmento, B. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int. J. Nanomedicine, 2014, 9, 1757-1769.
2. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature (London), 1996, 381, (6584), 661-666.
3. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (Washington, D. C.), 1996, 272(5263), 872-877.
4. Ruben, S.; Perkins, A.; Purcell, R.; Joung, K.; Sia, R.; Burghoff, R.; Haseltine, W. A.; Rosen, C. A. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol., 1989, 63(1), 1-8.
5. Zapp, M. L.; Green, M. R. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature (London), 1989, 342(6250), 714-716.
6. Kim, S.; Byrn, R.; Groopman, J.; Baltimore, D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J. Virol., 1989, 63(9), 3708-3713.
7. Cohen, E. A.; Dehni, G.; Sodroski, J. G.; Haseltine, W. A. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J. Virol., 1990, 64(6), 3097-3099.
8. Schwartz, S.; Felber, B. K.; Fenyoe, E. M.; Pavlakis, G. N. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J. Virol., 1990, 64(11), 5448-5456.
9. Strebel, K.; Daugherty, D.; Clouse, K.; Cohen, D.; Folks, T.; Martin, M. A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (London), 1987, 328(6132), 728-730.
10. Freed, E. O. HIV-1 replication. Somat. Cell. Mol. Genet., 2001, 26(1-6), 13-33.
11. Perelson, A. S.; Neumann, A. U.; Markowitz, M.; Leonard, J. M.; Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science, 1996, 271(5255), 1582-1586.
12. Gonzalez-Scarano, F.; Martin-Garcia, J. The neuropathogenesis of AIDS. Nature reviews. Immunology, 2005, 5(1), 69-81.
13. Boisse, L.; Gill, M. J.; Power, C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol. Clin., 2008, 26(3), 799-819, x.
14. Meltzer, M. S.; Gendelman, H. E. Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr. Top. Microbiol. Immunol., 1992, 181, 239-263.
15. Volberding, P. A.; Deeks, S. G. Antiretroviral therapy and management of HIV infection. Lancet, 2010, 376(9734), 49-62.
16. Thompson, M. A.; Aberg, J. A.; Hoy, J. F.; Telenti, A.; Benson, C.; Cahn, P.; Eron, J. J. Jr.; Gunthard, H. F.; Hammer, S. M.; Reiss, P.; Richman, D. D.; Rizzardini, G.; Thomas, D. L.; Jacobsen, D. M.; Volberding, P. A. Antiretroviral treatment of adult HIV infection. 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA, J. Am. Med. Assoc., 2012, 308(4), 387-402.
17. Michaels, S. H.; Clark, R.; Kissinger, P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med., 1998, 339(6), 405-406.
18. Brew, B. J. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS, 2004, 18 Suppl. 1, S75-S78.
19. Heaton, R. K.; Franklin, D. R.; Ellis, R. J.; McCutchan, J. A.; Letendre, S. L.; Leblanc, S.; Corkran, S. H.; Duarte, N. A.; Clifford, D. B.; Woods, S. P.; Collier, A. C.; Marra, C. M.; Morgello, S.; Mindt, M. R.; Taylor, M. J.; Marcotte, T. D.; Atkinson, J. H.; Wolfson, T.; Gelman, B. B.; McArthur, J. C.; Simpson, D. M.; Abramson, I.; Gamst, A.; Fennema-Notestine, C.; Jernigan, T. L.; Wong, J.; Grant, I. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. NeuroVirol., 2011, 17(1), 3-16.
20. Amiji, M. M.; Vyas, T. K.; Shah, L. K. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov. Med., 2006, 6(34), 157-162.
21. Vyas, T. K.; Shah, L.; Amiji, M. M. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv., 2006, 3(5), 613-628.
22. Moyer, M. P.; Gendelman, H. E. HIV replication and persistence in human gastrointestinal cells cultured in vitro. J. Leukoc. Biol., 1991, 49(5), 499-504.
23. Kalter, D. C.; Gendelman, H. E.; Meltzer, M. S. Monocytes, dendritic cells, and Langerhans cells in human immunodeficiency virus infection. Dermatol. Clin., 1991, 9(3), 415-428.
24. Quinn, T. C. Acute primary HIV infection. JAMA, 1997, 278(1), 58-62.
25. Schacker, T.; Little, S.; Connick, E.; Gebhard-Mitchell, K.; Zhang, Z. Q.; Krieger, J.; Pryor, J.; Havlir, D.; Wong, J. K.; Richman, D.; Corey, L.; Haase, A. T. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J. Infect. Dis., 2000, 181(1), 354-357.
26. Clark, S. J.; Saag, M. S.; Decker, W. D.; Campbell-Hill, S.; Roberson, J. L.; Veldkamp, P. J.; Kappes, J. C.; Hahn, B. H.; Shaw, G. M. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med., 1991, 324(14), 954-960.
27. Heise, C.; Dandekar, S.; Kumar, P.; Duplantier, R.; Donovan, R. M.; Halsted, C. H. Human immunodeficiency virus infection of enterocytes and mononuclear cells in human jejunal mucosa. Gastroenterology, 1991, 100(6), 1521-1527.
28. Donaldson, Y. K.; Bell, J. E.; Ironside, J. W.; Brettle, R. P.; Robertson, J. R.; Busuttil, A.; Simmonds, P. Redistribution of HIV outside the lymphoid system with onset of AIDS. Lancet, 1994, 343(8894), 383-385.
29. Pomerantz, R. J. Reservoirs of human immunodeficiency virus type 1: The main obstacles to viral eradication. Clin. Infect. Dis., 2002, 34(1), 91-97.
30. Blankson, J. N.; Persaud, D.; Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med., 2002, 53, 557-593.
31. Kotler, D. P. HIV infection and the gastrointestinal tract. AIDS, 2005, 19(2), 107-117.
32. Adachi, A.; Koenig, S.; Gendelman, H. E.; Daugherty, D.; Gattoni-Celli, S.; Fauci, A. S.; Martin, M. A. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol., 1987, 61, (1), 209-213.
33. Letendre, S.; Marquie-Beck, J.; Capparelli, E.; Best, B.; Clifford, D.; Collier, A. C.; Gelman, B. B.; McArthur, J. C.; McCutchan, J. A.; Morgello, S.; Simpson, D.; Grant, I.; Ellis, R. J. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol., 2008, 65, (1), 65-70.
34. Grant, I. Neurocognitive disturbances in HIV. Int. Rev. Psychiatr., 2008, 20, (1), 33-47.
35. Letendre, S.; McCutchan, J. A.; Ellis, R. J. Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Neurologic complications of HIV disease and their treatment. Top. HIV Med., 2008, 16, (1), 15-22.
36. McArthur, J. C. HIV dementia: an evolving disease. J. Neuroimmunol., 2004, 157, (1-2), 3-10.
37. Valcour, V.; Sithinamsuwan, P.; Letendre, S.; Ances, B. Pathogenesis of HIV in the central nervous system. Curr. HIV/AIDS Rep., 2011, 8, (1), 54-61.
38. Saksena, N. K.; Haddad, D.e. N. Viral reservoirs an impediment to HAART: New strategies to eliminate HIV-1. Curr. Drug Targets: Infect. Disord., 2003, 3, (2), 179-206.
39. Gartner, S.; Markovits, P.; Markovitz, D. M.; Kaplan, M. H.; Gallo, R. C.; Popovic, M. The role of mononuclear phagocytes in HTLVIII/LAV infection. Science, 1986, 233, (4760), 215-219.
40. Nicholson, J. K.; Cross, G. D.; Callaway, C. S.; McDougal, J. S. In vitro infection of human monocytes with human T lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J. Immunol., 1986, 137, (1), 323-329.
41. Levy, J. A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev., 1993, 57, (1), 183-289.
42. Geeraert, L.; Kraus, G.; Pomerantz, R. J. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med., 2008, 59, 487-501.
43. Nelson, J. A.; Wiley, C. A.; Reynolds-Kohler, C.; Reese, C. E.; Margaretten, W.; Levy, J. A. Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet, 1988, 1, (8580), 259-262.
44. Brightman, M. W.; Reese, T. S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell. Biol., 1969, 40, (3), 648-677.
45. Rubin, L. L.; Staddon, J. M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci., 1999, 22, 11-28.
46. Nowacek, A.; Gendelman, H. E. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (London, U. K.), 2009, 4, (5), 557-574.
47. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther., 2008, 325, (2), 349-356.
48. Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S. P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci., 2003, 6, (2), 252-273.
49. Pathan, S. A.; Iqbal, Z.; Zaidi, S. M.; Talegaonkar, S.; Vohra, D.; Jain, G. K.; Azeem, A.; Jain, N.; Lalani, J. R.; Khar, R. K.; Ahmad, F. J. CNS drug delivery systems: novel approaches. Rec. Pat. Drug Deliv. Formul., 2009, 3, (1), 71-89.
50. Biddlestone-Thorpe, L.; Marchi, N.; Guo, K.; Ghosh, C.; Janigro, D.; Valerie, K.; Yang, H. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. Adv. Drug. Deliv. Rev., 2012, 64, (7), 605-613.
51. Bawarski, W. E.; Chidlowsky, E.; Bharali, D. J.; Mousa, S. A. Emerging nanopharmaceuticals. Nanomedicine (N. Y., NY, U. S.), 2008, 4, (4), 273-282.
52. Gunaseelan, S.; Gunaseelan, K.; Deshmukh, M.; Zhang, X.; Sinko, P. J. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv. Drug. Deliv. Rev., 2010, 62, (4-5), 518-531.
53. Govender, T.; Ojewole, E.; Naidoo, P.; Mackraj, I. Polymeric Nanoparticles for Enhancing Antiretroviral Drug Therapy. Drug Delivery, 2008, 15, (8), 493-501.
54. Destache, C. J. Chapter 12-Brain as an HIV sequestered site: Use of nanoparticles as a therapeutic option. Prog. Brain Res., 2009, 180, 225-233.
55. Nowacek, A.; Gendelman, H. E. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine, 2009, 4, (5), 557-574.
56. Wong, H. L.; Chattopadhyay, N.; Wu, X. Y.; Bendayan, R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Delivery Rev., 2010, 62, (4-5), 503-517.
57. Das Neves, J.; Amiji, M. M.; Bahia, M. F.; Sarmento, B. Nanotechnologybased systems for the treatment and prevention of HIV/AIDS. Adv. Drug Delivery Rev., 2010, 62, (4-5), 458-477.
58. Mahajan, S. D.; Aalinkeel, R.; Law, W. C.; Reynolds, J. L.; Nair, B. B.; Sykes, D. E.; Yong, K. T.; Roy, I.; Prasad, P. N.; Schwartz, S. A. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int. JNanomed., 2012, 7, 5301-5314.
59. Haag, R.; Kratz, F. Polymer therapeutics: concepts and applications. Angew. Chem., Int. Ed., 2006, 45, (8), 1198-1215.
60. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discovery, 2003, 2, (5), 347-360.
61. Yang, L.; Chen, L.; Zeng, R.; Li, C.; Qiao, R.; Hu, L.; Li, Z. Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: Chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate. Bioorg. Med. Chem., 2010, 18, (1), 117-123.
62. Li, W.; Wu, J.; Zhan, P.; Chang, Y.; Pannecouque, C.; De Clercq, E.; Liu, X. Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates. Int. J. Biol. Macromol., 2012, 50, (4), 974-980.
63. Neeraj, A.; Chandrasekar, M. J. N.; Sara, U. V. S.; Rohini, A. Poly (HEMA-Zidovudine) conjugate: A macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug. Drug Delivery, 2011, 18, (4), 272-280.
64. Nanjwade, B. K.; Bechra, H. M.; Derkar, G. K.; Manvi, F. V.; Nanjwade, V. K. Dendrimers: Emerging polymers for drug-delivery systems. Eur. J. Pharm. Sci., 2009, 38, (3), 185-196.
65. Huang, R.-Q.; Qu, Y.-H.; Ke, W.-L.; Zhu, J.-H.; Pei, Y.-Y.; Chen, J. Efficient gene delivery targeted to the brain using a transferrinconjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J., 2007, 21, (4), 1117-1125, 1110.1096/fj.1106-7380com.
66. Dutta, T.; Jain, N. K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta, Gen. Subj., 2007, 1770, (4), 681-686.
67. Dutta, T.; Agashe, H. B.; Garg, M.; Balasubramanium, P.; Kabra, M.; Jain, N. K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target., 2007, 15, (1), 89-98.
68. Vinogradov, S. V.; Poluektova, L. Y.; Makarov, E.; Gerson, T.; Senanayake, M. T. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antiviral Chem. Chemother., 2010, 21, (1), 1-14.
69. Dinesh Kumar, P.; Vijayaraj Kumar, P.; Panneer Selvam, T.; Sambasiva Rao, K. R. S. Prolonged drug delivery system of PEGylated PAMAM dendrimers with a anti-HIV drug. Res. Pharm., 2013, 3, (2), 08-17.
70. Pyreddy, S.; Kumar, P. D.; Kumar, P. V. Polyethylene glycolated PAMAM dendrimers-Efavirenz conjugates. Int. J. Pharm. Investig., 2014, 4, (1), 15-18.
71. Trivedi, R.; Kompella, U. B. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond), 2010, 5, (3), 485-505.
72. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc. Natl. Acad. Sci., 1989, 86, (2), 695-698.
73. Zhang, Y.; Han, H.; Elmquist, W. F.; Miller, D. W. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res., 2000, 876, (1-2), 148-153.
74. Fontaine, M.; Elmquist, W. F.; Miller, D. W. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sciences, 1996, 59, (18), 1521-1531.
75. Batrakova, E.; Li, S.; Miller, D.; Kabanov, A. Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized BBMEC and Caco-2 Cell Monolayers. Pharm. Res., 1999, 16, (9), 1366-1372.
76. Spitzenberger, T. J.; Heilman, D.; Diekmann, C.; Batrakova, E. V.; Kabanov, A. V.; Gendelman, H. E.; Elmquist, W. F.; Persidsky, Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood F. Met., 2007, 27, (5), 1033-1042.
77. Chiappetta, D. A.; Hocht, C.; Opezzo, J. A. W.; Sosnik, A. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine, 2012, 8, (2), 223-237.
78. Sagar, V.; Pilakka-Kanthikeel, S.; Pottathil, R.; Saxena, S. K.; Nair, M. Towards nanomedicines for neuroAIDS. Rev. Med. Virol., 2014, 24, (2), 103-124.
79. Fresta, M.; Wehrli, E.; Puglisi, G. Enhanced Therapeutic Effect of Cytidine-5β-Diphosphate Choline when Associated with GM1 Containing Small Liposomes as Demonstrated in a Rat Ischemia Model. Pharm. Res., 1995, 12, (11), 1769-1774.
80. Fresta, M.; Puglisi, G. Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion. Intl. J. Pharm., 1996, 134, (1-2), 89-97.
81. Craparo, E. F.; Bondì, M. L.; Pitarresi, G.; Cavallaro, G. Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System. CNS Neurosci. Ther., 2011, 17, (6), 670-677.
82. Schmidt, J.; Metselaar, J. M.; Wauben, M. H. M.; Toyka, K. V.; Storm, G.; Gold, R. Drug targeting by longβcirculating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, (8), 1895-1904.
83. Soni, V.; Kohli, D. V.; Jain, S. K. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J. Drug Target., 2008, 16, (1), 73-78.
84. Chen, H.; Qin, Y.; Zhang, Q.; Jiang, W.; Tang, L.; Liu, J.; He, Q. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur. J. Pharm. Sci., 2011, 44, (1-2), 164-173.
85. W. A. Jefferies, M. R. B. A. F. Williams, and S. V. Hunt, Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immun., 1985, Feb. 1985, (54(2)), 333-341.
86. Jefferies, W. A.; Brandon, M. R.; Hunt, S. V.; Williams, A. F.; Gatter, K. C.; Mason, D. Y. Transferrin receptor on endothelium of brain capillaries. Nature, 1984, 312, (5990), 162-163.
87. Prior, S.; Gander, B.; Blarer, N.; Merkle, H. P.; Subirá, M.a. L.; Irache, J. M.; Gamazo, C. In vitro phagocytosis and monocytemacrophage activation with poly (lactide) and poly (lactide-coglycolide) microspheres. Eur. J. Pharm. Sci., 2002, 15, (2), 197-207.
88. Kim, S.; Scheerer, S.; Geyer, M. A.; Howell, S. B. Direct Cerebrospinal Fluid Delivery of an Antiretroviral Agent Using Multivesicular Liposomes. J. Infect. Dis., 1990, 162, (3), 750-752.
89. Jin, S. X.; Bi, D. Z.; Wang, J.; Wang, Y. Z.; Hu, H. G.; Deng, Y. H. Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Die Pharmazie - An International Journal of Pharmaceutical Sciences, 2005, 60, (11), 840-843.
90. Saiyed, Z. M. Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier. Intl. JNanomed., 2010, 5, 157-166.
91. Kaur, C. D.; Nahar, M.; Jain, N. K. Lymphatic targeting of zidovudine using surface-engineered liposomes. J. Drug Target., 2008, 16, (10), 798-805.
92. Bestman-Smith, J.; Gourde, P.; Désormeaux, A.; Tremblay, M. J.; Bergeron, M. G. Sterically stabilized liposomes bearing anti-HLADR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2000, 1468, (1-2), 161-174.
93. Gagné, J.-F.; Désormeaux, A.; Perron, S.; Tremblay, M. J.; Bergeron, M. G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 2002, 1558, (2), 198-210.
94. ™) dispersions. Intl. J. of Pharm., 1998, 168, (2), 221-229.
95. Müller, R. H. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50, (1), 161-177.
96. Lockman, P. R. Brain uptake of thiamine-coated nanoparticles. J Controll Release, 2003, 93, (3), 271-282.
97. Yang, S. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res., 1999, 16, (5), 751-757.
98. Fundaro, A.; Cavalli, R.; Bargoni, A.; Vighetto, D.; Zara, G. P.; Gasco, M. R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res., 2000, 42, (4), 337-343.
99. Chen, D. B. In vitro and in vivo study of two types of longcirculating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull, 2001, 49, (11), 1444-1447.
100. Zara, G. P.; Cavalli, R.; Fundar, A.; Bargoni, A.; Caputo, O.; Gasco, M. R. Pharmacokinetics of doxorubincin incorporated in solid lipid nanaspheres (SLN). Pharm. Res., 1999, 40, (3), 281-286.
101. Podio, V. Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats. J. Pharm. Pharmaco., 2000, 52, (9), 1057-1063.
102. Yang, S. C. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control Release, 1999, 59, (3), 299-307.
103. Lockman, P. R. In vivo and in vitro assessment of baseline bloodbrain barrier parameters in the presence of novel nanoparticles. Pharm. Res., 2003, 20, (5), 705-713.
104. Yusuf, M.; Khan, M.; Khan, R. A.; Ahmed, B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model. J. Drug Target., 2013, 21, (3), 300-311.
105. Kuo, Y. C.; Su, F. L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm., 2007, 340, (1-2), 143-152.
106. Kuo, Y. C. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Intl. J. Pharm., 2008, 351, (1-2), 271-281.
107. Chattopadhyay, N.; Zastre, J.; Wong, H.-L.; Wu, X.; Bendayan, R. Solid Lipid Nanoparticles Enhance the Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human Brain Endothelial Cell Line. Pharm. Res., 2008, 25, (10), 2262-2271.
108. Kuo, Y. C.; Ko, H. F. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials, 2013, 34, (20), 4818-4830.
109. Aji Alex, M. R.; Chacko, A. J.; Jose, S.; Souto, E. B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci., 2011, 42, (1-2), 11-18.
110. Dou, H.; Destache, C. J.; Morehead, J. R.; Mosley, R. L.; Boska, M. D.; Kingsley, J.; Gorantla, S.; Poluektova, L.; Nelson, J. A.; Chaubal, M.; Werling, J.; Kipp, J.; Rabinow, B. E.; Gendelman, H. E. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, (8), 2827-2835.
111. Nowacek, A. S.; McMillan, J.; Miller, R.; Anderson, A.; Rabinow, B.; Gendelman, H. E. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharmacol., 2010, 5, (4), 592-601.
112. Batrakova, E. V.; Gendelman, H. E.; Kabanov, A. V. Cell-mediated drug delivery. Expert. Opin. Drug Deliv., 2011, 8, (4), 415-433.
113. Gautam, N.; Roy, U.; Balkundi, S.; Puligujja, P.; Guo, D.; Smith, N.; Liu, X. M.; Lamberty, B.; Morsey, B.; Fox, H. S.; McMillan, J.; Gendelman, H. E.; Alnouti, Y. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother., 2013, 57, (7), 3110-3120.
114. Dash, P. K.; Gendelman, H. E.; Roy, U.; Balkundi, S.; Alnouti, Y.; Mosley, R. L.; Gelbard, H. A.; McMillan, J.; Gorantla, S.; Poluektova, L. Y. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS, 2012, 26, (17), 2135-2144.
115. Martinez-Skinner, A. L.; Veerubhotla, R. S.; Liu, H.; Xiong, H.; Yu, F.; McMillan, J. M.; Gendelman, H. E. Functional Proteome of Macrophage Carried Nanoformulated Antiretroviral Therapy Demonstrates Enhanced Particle Carrying Capacity. J. Proteome. Res., 2013, 12, (5), 2282-2294.
116. Roy, U.; McMillan, J.; Alnouti, Y.; Gautum, N.; Smith, N.; Balkundi, S.; Dash, P.; Gorantla, S.; Martinez-Skinner, A.; Meza, J.; Kanmogne, G.; Swindells, S.; Cohen, S. M.; Mosley, R. L.; Poluektova, L.; Gendelman, H. E. Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1-Infected Human Peripheral Blood Lymphocyte-Reconstituted Mice. J. Infect. Dis., 2012, 206, (10), 1577-1588.
117. Kularatne, S. A.; Low, P. S. Targeting of nanoparticles: folate receptor. Methods. Mol. Biol. (Totowa, NJ, U. S.), 2010, 624, (Cancer Nanotechnology), 249-265.
118. Lu, J.; Li, Z.; Zink, J. I.; Tamanoi, F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine (New York, NY, U. S.), 2012, 8, (2), 212-220.
119. Nukolova, N. V.; Oberoi, H. S.; Cohen, S. M.; Kabanov, A. V.; Bronich, T. K. Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials, 2011, 32, (23), 5417-5426.
120. Xia, W.; Hilgenbrink, A. R.; Matteson, E. L.; Lockwood, M. B.; Cheng, J.-X.; Low, P. S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood, 2009, 113, (2), 438-446.
121. Puligujja, P.; McMillan, J.; Kendrick, L.; Li, T.; Balkundi, S.; Smith, N.; Veerubhotla, R. S.; Edagwa, B. J.; Kabanov, A. V.; Bronich, T.; Gendelman, H. E.; Liu, X.-M. Macrophage folate receptortargeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine (N. Y., NY, U. S.), 2013, 9, (8), 1263-1273.
122. Shegokar, R.; Singh, K. K. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Int. J. Pharm., 2011, 421, (2), 341-352.
123. Sharma, P.; Garg, S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv. Drug Delivery Rev., 2010, 62, (4-5), 491-502.
124. Wong, H. L.; Chattopadhyay, N.; Wu, X. Y.; Bendayan, R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Delivery Rev., 2010, 62, (4-5), 503-517.
125. Xia, H.; Gao, X.; Gu, G.; Liu, Z.; Hu, Q.; Tu, Y.; Song, Q.; Yao, L.; Pang, Z.; Jiang, X.; Chen, J.; Chen, H. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int. J. Pharm. (Amsterdam, Neth.), 2012, 436, (1-2), 840-850.
126. Kuo, Y.-C.; Lee, C.-L. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf., B, 2012, 90, 75-82.
127. Dhanya, K. P.; Santhi, K.; Dhanaraj, S. A.; Sajeeth, C. I. Formulation and evaluation of chitosan nanospheres as a carrier for the targeted delivery of Lamivudine to the brain. Pharm. Globale, 2011, 2, (5).
128. Kaur, A.; Jain, S.; Tiwary, A. K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta. Pharm., 2008, 58, (1), 61-74.
129. Jain, S. K.; Gupta, Y.; Jain, A.; Saxena, A. R.; Khare, P.; Jain, A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine, 2008, 4, (1), 41-48.
130. Destache, C. J.; Belgum, T.; Goede, M.; Shibata, A.; Belshan, M. A. Antiretroviral release from poly (DL-lactide-co-glycolide) nanoparticles in mice. J. Antimicrob. Chemother., 2010, 65, (10), 2183-2187.
131. Shah, L. K.; Amiji, M. M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res., 2006, 23, (11), 2638-2645.
132. Saiyed, M. P. N. N.a. Z. M. In The neurology of aids. Gendelman HE, E. I., Fox HS, Gelbard HA, Grant I, Lipton SA, Swindells S Ed.; Oxford University Press: New york, 2011, pp 999-1004.
133. Ikehara, Y.; Niwa, T.; Biao, L.; Ikehara, S. K.; Ohashi, N.; Kobayashi, T.; Shimizu, Y.; Kojima, N.; Nakanishi, H. A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle. Cancer Res., 2006, 66, (17), 8740-8748.
134. Brynskikh, A. M. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (London, England), 2010, 5, (3), 379-396.
135. Dou, H. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immun. (1950), 2009, 183, (1), 661-669.
136. Batrakova, E. V.; Li, S.; Reynolds, A. D.; Mosley, R. L.; Bronich, T. K.; Kabanov, A. V.; Gendelman, H. E. A MacrophageβNanozyme Delivery System for Parkinson's Disease. Bioconjugate Chem., 2007, 18, (5), 1498-1506.
137. Nowacek, A. S. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (London, England), 2009, 4, (8), 903-917.
138. Dou, H. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 2006, 108, (8), 2827-2835.
139. Dou, H. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (New York, N. Y.), 2007, 358, (1), 148-158.
140. Nowacek, A. S. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharm., 2010, 5, (4), 592-601.
141. Dou, H.; Grotepas, C. B.; McMillan, J. M.; Destache, C. J.; Chaubal, M.; Werling, J.; Kipp, J.; Rabinow, B.; Gendelman, H. E. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol., 2009, 183, (1), 661-669.
142. Kanmogne, G. D.; Singh, S.; Roy, U.; Liu, X.; McMillan, J.; Gorantla, S.; Balkundi, S.; Smith, N.; Alnouti, Y.; Gautam, N.; Zhou, Y.; Poluektova, L.; Kabanov, A.; Bronich, T.; Gendelman, H. E. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int. J. Nanomedicine, 2012, 7, 2373-2388.
143. Saiyed, Z.; Gandhi, N.; Nair, M. N. AZT 5α-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells. J. NeuroVirol., 2009, 15, (4), 343-347.
144. Yoo, H. S.; Park, T. G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J. Controlled Release, 2004, 100, (2), 247-256.
145. Lu, Y.; Low, P. S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother., 2002, 51, (3), 153-162.
146. Zhao, X.; Li, H.; Lee, R. J. Targeted drug delivery via folate receptors. Expert Opin. Drug Delivery, 2008, 5, (3), 309-319.
147. Majoros, I. J.; Thomas, T. P.; Mehta, C. B.; Baker, J. R. Jr., Poly (amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem., 2005, 48, (19), 5892-5899.
148. Yoshizawa, T.; Hattori, Y.; Hakoshima, M.; Koga, K.; Maitani, Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm., 2008, 70, (3), 718-725.